Valuation: Brooks Laboratories Limited

Market Cap 1.09B 11.42M 10.01M 9.24M 8.54M 16.19M 16.52M 111M 43.18M 535M 42.87M 41.93M 1.86B P/E 2024
-12.2x
P/E 2025 -28.6x
Enterprise Value 1.17B 12.2M 10.7M 9.88M 9.13M 17.31M 17.66M 119M 46.16M 572M 45.83M 44.83M 1.99B EV / Sales 2024
3.16x
EV / Sales 2025 3.93x
Free-Float
43.99%
Yield 2024 *
-
Yield 2025 -
06-19 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
05-29 Brooks Laboratories appoints Prashant Rathi as CEO RE
05-29 Brooks Laboratories names Prashant Rathi as CEO RE
05-29 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
05-29 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-06 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
16/10/25 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
13/08/25 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
28/05/25 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
13/02/25 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
26/12/24 Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024 CI
11/12/24 Brooks Laboratories Limited announced that it expects to receive INR 750 million in funding from Jalan Chemical Industries Private Limited, K M Visaria Family Trust CI
09/11/24 Brooks Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
1 day-1.86%
1 week-9.74%
Current month-0.51%
1 month+0.51%
3 months-3.91%
6 months-7.71%
Current year-14.52%
1 week 66.53
Extreme 66.53
79
1 month 65
Extreme 65
79
Current year 36.9
Extreme 36.9
82.3
1 year 36.9
Extreme 36.9
165.95
3 years 36.9
Extreme 36.9
202.8
5 years 36.9
Extreme 36.9
202.8
10 years 14.05
Extreme 14.05
202.8
Manager TitleAgeSince
Chief Executive Officer - 01/06/2026
President 57 23/08/2023
Compliance Officer 33 26/12/2024
Director TitleAgeSince
Director/Board Member 53 23/11/2022
Director/Board Member 62 10/09/2010
Director/Board Member - 23/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%-9.74% - - 21.41M
+2.80%+3.70%+16.23%+85.67% 47.31B
-0.81%-4.53%+65.57%+113.67% 36.04B
+0.86%-0.82%-3.20%+42.03% 12.08B
+0.94%+5.26%+18.31%+99.04% 11.96B
+0.38%+1.95%+34.36%+123.93% 9.05B
+0.58%-0.25%+17.85%+44.67% 6.92B
-1.61%+1.96%+54.90%-2.70% 7.19B
+2.16%+3.45%+24.90%+242.23% 6.55B
-7.00%+5.26%-20.00%+10.09% 5.9B
Average -0.37%+1.69%+23.21%+84.29% 15.89B
Weighted average by Cap. +0.63%+2.11%+29.27%+90.21%

Financials

2024 2025
Net sales 795M 8.3M 7.28M 6.72M 6.21M 11.77M 12.01M 80.81M 31.4M 389M 31.17M 30.49M 1.35B 826M 8.62M 7.56M 6.98M 6.45M 12.23M 12.47M 83.93M 32.61M 404M 32.38M 31.67M 1.4B
Net income -196M -2.05M -1.79M -1.66M -1.53M -2.9M -2.96M -19.92M -7.74M -95.88M -7.68M -7.52M -333M -99.67M -1.04M -913K -843K -779K -1.48M -1.51M -10.13M -3.94M -48.77M -3.91M -3.82M -169M
Net Debt 55.16M 576K 505K 467K 431K 817K 833K 5.61M 2.18M 27M 2.16M 2.12M 93.71M 75.39M 787K 691K 638K 589K 1.12M 1.14M 7.66M 2.98M 36.9M 2.96M 2.89M 128M
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
Employees
323
Date Price Change Volume
09/07/26 68.60 -1.86% 3,896
08/07/26 ₹69.90 -4.44% 1,338
07/07/26 ₹73.15 -4.99% 623
06/07/26 ₹76.99 -0.93% 2,879
03/07/26 ₹77.71 +2.25% 5,578